SWM
TXMD icon

Spire Wealth Management’s TherapeuticsMD TXMD Stock Holding History

Spire Wealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,400
Closed -$25K – 2869
2021
Q4 		$25K Buy
+1,400
New +$42K ﹤0.01% 2045
2021
Q2 		– Sell
-800
Closed -$55K – 2963
2021
Q1 		$55K Buy
+800
New +$62.6K ﹤0.01% 1684

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Spire Wealth Management's TXMD Position: Q1 2022 in Review

Spire Wealth Management sold out of TherapeuticsMD (TXMD) in Q1 2022, closing a stake of 1,400 shares — an estimated $25K sold.

Spire Wealth Management first reported a position in TXMD in Q1 2021 and held it in 2 quarters. The position peaked at $55K in Q1 2021. 124 funds tracked by Wall St. Rank hold TXMD as of Q1 2022.

  • Spire Wealth Management reported no remaining TherapeuticsMD position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 1,400 TherapeuticsMD shares in Q1 2022, an estimated $25K.
  • Spire Wealth Management first reported a position in TherapeuticsMD in Q1 2021 and held it in 2 quarters.
  • Spire Wealth Management's TherapeuticsMD position peaked at $55K in Q1 2021.
  • 124 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.